卡培他滨联合多西他赛治疗蒽环类耐药转移性乳腺癌临床分析  

Efficacy of Capecitabine Combined with Docetaxel in Treating Anthracycline-resistant Breast Cancer

作　　者：曾哲超 詹丽芬[1] 甘立菁[1] 许慎[1] 

机构地区：[1]福建医科大学附属漳州市医院肿瘤内科,福建漳州363000

出　　处：《中外医疗》2015年第12期103-104,共2页China & Foreign Medical Treatment

摘　　要：目的分析及评价卡培他滨联合多西他赛治疗蒽环类耐药性乳腺癌的疗效和不良反应。方法将42例晚期乳腺癌患者随机分为2组,联合组采用卡培他滨联合多西他赛进行治疗。对照组采用多西他赛单药治疗。每2周期评价疗效。结果联合组有效率(CR+PR)为61.9%,主要不良反应为骨髓抑制、手足综合征、消化道反应。对照组有效率(CR+PR)为42.9%,主要不良反应为骨髓抑制、消化道反应等。2组有效率差异有统计学意义(P<0.05)。结论卡培他滨联合多西他赛治疗复发转移性蒽环类耐药的乳腺癌疗效较好,优于单一多西他赛治疗,不良反应可以耐受。Objective To research the efficacy and toxicities of capecitabine combined with docetaxel in the treatment of metastatic breast cancer.Methods 42 patients with metastatic breast cancer were randomly divided into two groups.In the combining group,21 patients were treated with capecitabine and docetaxel combination regimen.In the control group,21 patients were treated with docetaxel.Results In the combining group,the effective rate was 61.9%.The main toxic reactions were myelosuppression,hand-foot syndrome,baldness and gastrointestinal toxicities.In the control group,the effective rate was 42.9%.The main toxic reactions were myelosuppression,baldness and gastrointestinal toxicities.There were statistical difference（P〈0.05）.Conclusion Good clinical efficacy were achieved in the therapy of metastaticbreast cancer with capecitabine and docetaxel combination regimen and toxic reaction were tolerable.

关 键 词：卡培他滨 多西他赛 乳腺癌 化疗 

分 类 号：R737.9[医药卫生—肿瘤]